EBITDA Metrics Evaluated: Carlisle Companies Incorporated vs Rentokil Initial plc

EBITDA Growth: Carlisle vs. Rentokil from 2014-2023

__timestampCarlisle Companies IncorporatedRentokil Initial plc
Wednesday, January 1, 2014512300000410400000
Thursday, January 1, 2015631900000408700000
Friday, January 1, 2016580200000489000000
Sunday, January 1, 2017609300000503200000
Monday, January 1, 2018696100000149800000
Tuesday, January 1, 2019851000000580600000
Wednesday, January 1, 2020733100000581000000
Friday, January 1, 2021816100000656000000
Saturday, January 1, 20221483400000767000000
Sunday, January 1, 202312107000001157000000
Monday, January 1, 20241356800000
Loading chart...

Unlocking the unknown

EBITDA Performance: A Comparative Analysis

Carlisle Companies vs. Rentokil Initial

In the ever-evolving landscape of global business, understanding the financial health of companies is crucial. This analysis delves into the EBITDA performance of Carlisle Companies Incorporated and Rentokil Initial plc from 2014 to 2023.

Carlisle Companies has shown a robust growth trajectory, with its EBITDA increasing by approximately 136% over the decade. Notably, 2022 marked a peak with a 1.48 billion EBITDA, reflecting a significant 82% rise from 2014. Meanwhile, Rentokil Initial has also demonstrated resilience, with a 182% increase in EBITDA, reaching 1.16 billion in 2023.

This comparative analysis highlights Carlisle's consistent upward trend, particularly in 2022, while Rentokil's steady growth underscores its strategic adaptability. Investors and stakeholders can glean valuable insights into these companies' financial strategies and market positioning, making informed decisions in a competitive market.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
28 Jan 2025